The beak-like design makes these masks ultra-comfortable for kids and adults alike.
In March 2020, as conversations with people on the street became an increasingly rare occurrence for most people in the U.S., Melinda Hwang found herself having just as many chats with passersby as ever. Everyone who stopped her and her family mid-walk asked her the same question: Where did she get those unique, beak-shaped face masks?
Hwang would then explain how her mom, Angela, who lives in Taiwan, sent them to her as soon as COVID cases started popping up in the U.S.
“If your mom ever sends you anything else, can you ask if she can send a few for us?” a neighbor asked.
AlleyWatch
Armed with some data from our friends at CrunchBase, I broke down the largest global startup funding rounds for April 2021. I have included some additional information such as industry, round type, a brief description of the company, investors in the round, company location, and total equity funding raised for the company to further the analysis.
Round: Series D
Description: New York-based Capsule is a healthcare technology business rebuilding the pharmacy from the inside out Founded by Eric Kinariwala in 2016, Organization Name has now raised a total of $570.0M in total equity funding and is backed by investors that include T. Rowe Price, Sound Ventures, TCV, Global Founders Capital, and M13.
Patients with chronic kidney disease who stop using a class of common blood pressure medications may lower their risk for dialysis, but they also raise their odds of cardiovascular disease, a new study finds.
Effect Of Stopping RAS Inhibitors In Patients With Chronic Kidney Disease by Pooja Shete on January 1, 2021 at 8:08 PM
Certain small studies suggest that a group of medications called RAS inhibitors which are used for the treatment of hypertension, may be harmful in patients with advanced chronic kidney disease. Therefore physicians often stop the treatment with these drugs in such patients.
Research conducted at Karolinska Institutet shows that although stopping RAS inhibitors is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events, and death.
The research conducted at Karolinska Institutet is published in the
E-Mail
IMAGE: Principal investigator Juan Jesus Carrero, professor at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. view more
Credit: Ulf Sirborn.
Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients. Researchers at Karolinska Institutet now show that although stopping the treatment is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events and death. The results are published in
The Journal of the American Society of Nephrology.